[Federal Register: April 3, 2006 (Volume 71, Number 63)]
[Notices]
[Page 16582-16583]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr03ap06-66]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
Joint Meeting of the Dental Products Panel of the Medical Devices
Advisory Committee of the Center for Devices and Radiological Health
and the Peripheral and Central Nervous System Drugs Advisory Committee
of the Center for Drug Evaluation and Research; Notice of Meeting
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
This notice announces a forthcoming meeting of a public advisory
committee of the Food and Drug Administration (FDA). The meeting will
be open to the public.
[[Page 16583]]
Names of Committees: The Dental Products Panel of the Medical
Devices Advisory Committee of the Center for Devices and Radiological
Health (CDRH) and the Peripheral and Central Nervous System Drugs
Advisory Committee of the Center for Drug Evaluation and Research
(CDER). This will be a joint meeting of the two committees.
General Function of the Joint Committee: To provide advice and
recommendations to the agency on FDA's regulatory issues.
Date and Time: The meeting will be held on September 6 and 7, 2006,
from 8 a.m. to 5 p.m.
Location: Holiday Inn, Walker/Whetstone Rm., Two Montgomery Village
Ave., Gaithersburg, MD.
Contact Person: Michael E. Adjodha, Center for Devices and
Radiological Health (HFZ-480), Food and Drug Administration, 9200
Corporate Blvd., Rockville, MD 20850, 301-827-5283, ext. 123, e-mail:
Michael.adjodha@fda.hhs.gov or FDA Advisory Committee Information Line,
1-800-741-8138 (301-443-0572) in the Washington, DC area), code
3014512518. Please call the Information Line for up-to-date information
on this meeting.
Agenda: This joint committee will review and discuss peer-reviewed
scientific literature on dental amalgam devices. Dental amalgam, also
called ``encapsulated amalgam,'' consists of dental mercury and amalgam
alloys. This joint committee will review and discuss peer-reviewed
scientific literature on dental amalgam and its potential mercury
toxicity, specifically as it relates to neurotoxic effects. Certain
consumer groups have raised concerns about the effects of using mercury
as a component of dental restorative materials; therefore, we are
combining the expertise of the Dental Products Panel of the Medical
Device Advisory Committee with the neurology expertise of the
Peripheral and Central Nervous System Drugs Advisory Committee.
Procedure: Interested persons may present data, information, or
views, orally or in writing, on issues pending before the committee.
Written submissions may be made to the contact person by August 23,
2006. On September 6 and 7, 2006, oral presentations from the public
will be scheduled at the beginning of committee deliberations and near
the end of the deliberations. Time allotted for each presentation may
be limited. Those desiring to make formal oral presentations should
submit written notification to the contact person by August 23, 2006,
and include the names and addresses of proposed participants, and an
indication of the approximate time requested to make their
presentation.
Persons attending FDA's advisory committee meetings are advised
that we are not responsible for providing access to electrical outlets.
FDA welcomes the attendance of the public at its advisory committee
meetings and will make every effort to accommodate persons with
physical disabilities or special needs. If you require special
accommodations due to a disability, please contact Ann Marie Williams,
Conference Management Staff, 240-276-0450 ext. 113, at least 7 days in
advance of the meeting.
Notice of this meeting is given under the Federal Advisory
Committee Act (5 U.S.C. app. 2).
Dated: March 22, 2006.
Scott Gottlieb,
Deputy Commissioner for Policy.
[FR Doc. E6-4760 Filed 3-31-06; 8:45 am]
BILLING CODE 4160-01-S